NCT02215122View on ClinicalTrials.gov

Bioequivalence Study to Assess Systemic Exposure of FP and SAL FDC From Different DPIs

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
AsthmaCOPD
Interventions
DRUG

MGR001

Fluticasone Propionate is an inhaled corticosteroid (ICS) Salmeterol is a long acting β2 agonist (LABA)

DRUG

Advair® Diskus®

Fluticasone Propionate is an inhaled corticosteroid (ICS) Salmeterol is a long acting β2 agonist (LABA)

DRUG

Seretide™ Accuhaler™

Fluticasone Propionate is an inhaled corticosteroid (ICS) Salmeterol is a long acting β2 agonist (LABA)

Trial Locations (1)

78217

Worldwide Clinical Trials Early Phase Services, San Antonio

All Listed Sponsors
lead

Mylan Pharma UK Ltd.

INDUSTRY

NCT02215122 - Bioequivalence Study to Assess Systemic Exposure of FP and SAL FDC From Different DPIs | Biotech Hunter | Biotech Hunter